Concepts (116)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Immunotherapy, Adoptive | 3 | 2025 | 102 | 1.190 |
Why?
|
| Thrombosis | 3 | 2024 | 198 | 0.990 |
Why?
|
| Hemorrhage | 3 | 2024 | 275 | 0.920 |
Why?
|
| Antineoplastic Agents, Immunological | 3 | 2021 | 48 | 0.850 |
Why?
|
| Hematologic Neoplasms | 1 | 2024 | 47 | 0.810 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2023 | 68 | 0.800 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2023 | 110 | 0.790 |
Why?
|
| Rituximab | 2 | 2023 | 89 | 0.760 |
Why?
|
| Androgen Antagonists | 1 | 2018 | 26 | 0.570 |
Why?
|
| Prostatic Neoplasms, Castration-Resistant | 1 | 2018 | 18 | 0.570 |
Why?
|
| Multiple Myeloma | 1 | 2023 | 347 | 0.560 |
Why?
|
| Medical Marijuana | 2 | 2025 | 19 | 0.410 |
Why?
|
| Graft vs Host Disease | 2 | 2025 | 116 | 0.400 |
Why?
|
| Leukemia, Myeloid, Acute | 2 | 2025 | 192 | 0.360 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 2 | 2025 | 356 | 0.350 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2021 | 248 | 0.280 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 2 | 2021 | 174 | 0.280 |
Why?
|
| Cyclophosphamide | 2 | 2025 | 87 | 0.260 |
Why?
|
| Medical Oncology | 2 | 2025 | 68 | 0.260 |
Why?
|
| Aged | 12 | 2025 | 14663 | 0.250 |
Why?
|
| Antigens, CD19 | 1 | 2025 | 25 | 0.240 |
Why?
|
| Humans | 21 | 2025 | 64272 | 0.230 |
Why?
|
| Lupus Nephritis | 1 | 2025 | 37 | 0.230 |
Why?
|
| Female | 14 | 2025 | 33383 | 0.220 |
Why?
|
| Hemostasis | 1 | 2024 | 18 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-bcl-6 | 1 | 2023 | 8 | 0.210 |
Why?
|
| Vincristine | 1 | 2023 | 28 | 0.210 |
Why?
|
| Myelodysplastic Syndromes | 1 | 2025 | 85 | 0.210 |
Why?
|
| Mutation | 2 | 2025 | 2633 | 0.210 |
Why?
|
| Prednisone | 1 | 2023 | 85 | 0.200 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2025 | 172 | 0.200 |
Why?
|
| Doxorubicin | 1 | 2023 | 101 | 0.200 |
Why?
|
| Lung Neoplasms | 2 | 2021 | 695 | 0.200 |
Why?
|
| Male | 13 | 2025 | 30322 | 0.200 |
Why?
|
| Cell Cycle Proteins | 1 | 2025 | 398 | 0.190 |
Why?
|
| Hematology | 1 | 2022 | 12 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2024 | 511 | 0.180 |
Why?
|
| Platelet Aggregation Inhibitors | 1 | 2024 | 233 | 0.180 |
Why?
|
| Quarantine | 1 | 2021 | 11 | 0.170 |
Why?
|
| Curriculum | 1 | 2025 | 607 | 0.170 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2020 | 358 | 0.170 |
Why?
|
| Chordoma | 1 | 2020 | 6 | 0.160 |
Why?
|
| Immunotherapy | 2 | 2020 | 265 | 0.160 |
Why?
|
| Neoplasms | 2 | 2021 | 1393 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2023 | 457 | 0.160 |
Why?
|
| Infection Control | 1 | 2021 | 105 | 0.160 |
Why?
|
| Spinal Neoplasms | 1 | 2020 | 17 | 0.160 |
Why?
|
| Treatment Outcome | 3 | 2025 | 5696 | 0.150 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2023 | 788 | 0.150 |
Why?
|
| Hepatitis | 1 | 2019 | 58 | 0.150 |
Why?
|
| Betacoronavirus | 1 | 2020 | 183 | 0.140 |
Why?
|
| Middle Aged | 6 | 2025 | 17923 | 0.130 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 210 | 0.130 |
Why?
|
| Kidney Neoplasms | 2 | 2019 | 166 | 0.130 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 223 | 0.130 |
Why?
|
| Risk Assessment | 1 | 2024 | 2048 | 0.130 |
Why?
|
| Patient Discharge | 1 | 2020 | 507 | 0.130 |
Why?
|
| Melanoma | 1 | 2020 | 331 | 0.130 |
Why?
|
| Risk Factors | 2 | 2024 | 5341 | 0.120 |
Why?
|
| Adult | 5 | 2025 | 17136 | 0.120 |
Why?
|
| Urothelium | 1 | 2015 | 22 | 0.110 |
Why?
|
| Breast Neoplasms | 1 | 2023 | 1213 | 0.110 |
Why?
|
| Urinary Bladder Neoplasms | 1 | 2015 | 106 | 0.100 |
Why?
|
| Prognosis | 3 | 2025 | 1769 | 0.100 |
Why?
|
| Acute Kidney Injury | 1 | 2015 | 142 | 0.100 |
Why?
|
| Aged, 80 and over | 4 | 2025 | 5528 | 0.090 |
Why?
|
| Survival Rate | 2 | 2025 | 859 | 0.090 |
Why?
|
| T-Lymphocytes | 2 | 2025 | 1019 | 0.080 |
Why?
|
| Young Adult | 3 | 2025 | 4782 | 0.080 |
Why?
|
| Cohort Studies | 2 | 2023 | 2605 | 0.060 |
Why?
|
| Symptom Flare Up | 1 | 2025 | 16 | 0.060 |
Why?
|
| Methylprednisolone | 1 | 2025 | 38 | 0.060 |
Why?
|
| Transplantation, Homologous | 1 | 2025 | 249 | 0.060 |
Why?
|
| Retrospective Studies | 3 | 2023 | 6741 | 0.060 |
Why?
|
| Lupus Erythematosus, Systemic | 1 | 2025 | 171 | 0.050 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 667 | 0.050 |
Why?
|
| Immunosuppressive Agents | 1 | 2025 | 381 | 0.050 |
Why?
|
| Clone Cells | 1 | 2023 | 116 | 0.050 |
Why?
|
| Abatacept | 1 | 2023 | 66 | 0.050 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2025 | 313 | 0.050 |
Why?
|
| Steroids | 1 | 2023 | 55 | 0.050 |
Why?
|
| Feasibility Studies | 1 | 2025 | 577 | 0.050 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2023 | 291 | 0.040 |
Why?
|
| Pleural Neoplasms | 1 | 2021 | 19 | 0.040 |
Why?
|
| Fellowships and Scholarships | 1 | 2022 | 107 | 0.040 |
Why?
|
| Lymphatic Metastasis | 1 | 2021 | 93 | 0.040 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2021 | 49 | 0.040 |
Why?
|
| Hoarseness | 1 | 2020 | 1 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2021 | 210 | 0.040 |
Why?
|
| CTLA-4 Antigen | 1 | 2020 | 73 | 0.040 |
Why?
|
| Imatinib Mesylate | 1 | 2020 | 34 | 0.040 |
Why?
|
| Chronic Disease | 1 | 2023 | 756 | 0.040 |
Why?
|
| B7-H1 Antigen | 1 | 2020 | 59 | 0.040 |
Why?
|
| Risk | 1 | 2020 | 379 | 0.040 |
Why?
|
| Bone Neoplasms | 1 | 2021 | 126 | 0.040 |
Why?
|
| Education, Medical, Graduate | 1 | 2022 | 350 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2020 | 375 | 0.040 |
Why?
|
| Palliative Care | 1 | 2021 | 239 | 0.040 |
Why?
|
| Head and Neck Neoplasms | 1 | 2020 | 167 | 0.040 |
Why?
|
| ErbB Receptors | 1 | 2019 | 118 | 0.040 |
Why?
|
| Pulmonary Embolism | 1 | 2020 | 175 | 0.040 |
Why?
|
| Liver Neoplasms | 1 | 2021 | 306 | 0.030 |
Why?
|
| Carcinoma, Renal Cell | 1 | 2019 | 108 | 0.030 |
Why?
|
| Brain Neoplasms | 1 | 2021 | 313 | 0.030 |
Why?
|
| Comorbidity | 1 | 2021 | 1119 | 0.030 |
Why?
|
| Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 145 | 0.030 |
Why?
|
| Surveys and Questionnaires | 1 | 2025 | 2738 | 0.030 |
Why?
|
| Incidence | 1 | 2020 | 1386 | 0.030 |
Why?
|
| Pandemics | 1 | 2020 | 676 | 0.030 |
Why?
|
| Follow-Up Studies | 1 | 2020 | 2482 | 0.030 |
Why?
|
| Time Factors | 1 | 2021 | 3725 | 0.030 |
Why?
|
| Hospitalization | 1 | 2020 | 1368 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2015 | 984 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2020 | 2218 | 0.020 |
Why?
|
| United States | 1 | 2023 | 7923 | 0.020 |
Why?
|
| Adolescent | 1 | 2020 | 6306 | 0.020 |
Why?
|